PIM1 and neoplasm: These effects were potentiated by the use of an anti-PD1 antibody (triple combination therapy), prolonging mouse survival, decreasing tumor growth and improving T-cell migration.140 Multiple studies have suggested the use of immunotherapeutics, perhaps alongside PIM inhibitors, to overcome the mechanisms of resistance to treatment and improve the functional outcomes.27,133